GSK: positive results in multiple myeloma
(CercleFinance.com) - GlaxoSmithKline announced on Friday that belantamab mafodotin, a monoclonal antibody that neutralises certain molecules, has shown positive results in trials on patients with multiple myeloma, which is expected to prompt the laboratory to seek its commercialisation by the end of the year.
The British pharmaceutical group said that the trials showed a "clinically significant" response rate amongst the 196 patients followed, which led it to consider filing an application for registration with the health authorities by the end of 2019.
Multiple myeloma, the second most common form of blood cancer, can often be treated, even though patients never fully recover from the disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.